Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMY0KGJ)

• Drug Name: Chlorprothixene Drug Info
• Synonyms: Chloroprothixene; Chlorprothixen; Chlorprothixenum; Chlorprothixine; Chlorprotixen; Chlorprotixene; Chlorprotixine; Chlothixen; Clorprotisene; Clorprotixeno; Iaractan; Paxyl; Rentovet; Tactaran; Taractan; Tarasan; Tardan; Traquilan; Trictal; Truxal; Truxaletten; Truxil; Vetacalm; Clorprotisene [DCIT]; MK 184; N 714; N 714C; NCI56378; Alpha-Chlorprothixene; Chlorprothixenum [INN-Latin]; Cis-Chlorprothixene; Clorprotixeno [INN-Spanish]; N-714; Ro 4-0403; Taractan (TN); Truxal (TN); Ro-4-0403;Trans(E)-Chlorprothixen; Chlorprothixene (JAN/USAN/INN); Chlorprothixene [USAN:INN:BAN:JAN]; Cloxan, Taractan, Truxal, Chlorprothixene; Cis-2-Chloro-9-(3-dimethylaminopropylidene)thioxanthene; {3-[2-Chloro-thioxanthen-(9Z)-ylidene]-propyl}-dimethyl-amine; Thioxanthene-delta9,gamma-propylamine, 2-chloro-N,N-dimethyl-, (Z)-(8CI); (3E)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3E)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (3Z)-3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; (Z)-2-Chloro-9-(omega-dimethylaminopropylidene)thioxanthene; (Z)-2-Chloro-N,N-dimethylthioxanthene-.DELTA.(sup9),(sup.gamma.)-propylamine; (Z)-2-Chloro-N,N-dimethylthioxanthene-delta(sup 9,gamma)-propylamine; (alpha.-2-Chloro-9-.omega.-dimethylamino-propylamine)thioxanthene; 2-Chloro-9-[.omega.-(dimethylamino)propylidene]thioxanthene; 2-Chloro-9-[3-(dimethylamino)propylidene]thioxanthene; 2-Chloro-N,N-dimethylthioxanthene-.delta.(sup 9), .gamma.-propylamine; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethyl-1-propanamine; 3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine; 3-(2-chlorothioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine
• Therapeutic Class: Antipsychotic Agents
• Cross-matching ID:
  PubChem CID: 667467
  ChEBI ID: CHEMBL908
  CAS Number: CAS 113-59-7
  TTD Drug ID: D0B0CP
  VARIDT Drug ID: DR00591

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Steroid biosynthesis	2.22	0.00e+0	19/20 (95%)	DHCR24;SC5D;MSMO1;...
Biosynthesis of unsaturated fatty acids	1.96	5.40e-3	21/27 (77.78%)	SCD;SCP2;ACOT7;...
Sulfur metabolism	1.90	7.20e-3	9/10 (90%)	PAPSS1;PAPSS2;SELENBP1;...
PPAR signaling pathway	1.77	2.84e-2	66/74 (89.19%)	SCD;FABP5;ACSL5;...
Melanoma	-1.66	4.97e-2	68/72 (94.44%)	AKT1;MDM2;BAX;...
Steroid hormone biosynthesis	-1.67	4.26e-2	43/61 (70.49%)	CYP11B1;HSD3B2;SRD5A3;...
Chemokine signaling pathway	-1.67	4.47e-2	163/192 (84.9%)	CCL25;PLCB2;JAK3;...
Gastric acid secretion	-1.68	4.27e-2	63/76 (82.89%)	ATP4B;PLCB2;CAMK2A;...
Long-term depression	-1.69	3.77e-2	55/60 (91.67%)	RYR1;PRKG1;GRM1;...
Intestinal immune network for IgA production	-1.70	3.51e-2	38/48 (79.17%)	TGFB1;HLA-DOA;CCL25;...
Insulin secretion	-1.71	3.41e-2	75/86 (87.21%)	PRKACB;ADCY1;ABCC8;...
Inflammatory bowel disease	-1.73	2.98e-2	58/65 (89.23%)	STAT3;STAT4;TGFB1;...
Cytosolic DNA-sensing pathway	-1.74	2.96e-2	52/63 (82.54%)	POLR2F;CCL4;RELA;...
Non-small cell lung cancer	-1.75	2.80e-2	70/72 (97.22%)	RASSF1;JAK3;AKT1;...
Taste transduction	-1.75	3.04e-2	61/86 (70.93%)	PDE1C;ITPR3;PDE1B;...
Cytokine-cytokine receptor interaction	-1.75	3.31e-2	246/295 (83.39%)	IFNB1;TGFBR2;TNFRSF10C;...
Complement and coagulation cascades	-1.76	3.31e-2	76/85 (89.41%)	C6;F11;C8B;...
Viral protein interaction with cytokine and cytokine re...	-1.79	2.58e-2	84/100 (84%)	IL2RA;CCL25;TNFRSF10C;...
Glioma	-1.84	1.24e-2	67/75 (89.33%)	AKT1;CAMK2A;MDM2;...
GnRH secretion	-1.86	1.42e-2	60/64 (93.75%)	LHB;TRPC1;KISS1;...
Allograft rejection	-1.94	0.00e+0	32/38 (84.21%)	IL5;CD86;HLA-F;...
Aldosterone-regulated sodium reabsorption	-2.00	0.00e+0	34/37 (91.89%)	NEDD4L;PDPK1;KCNJ1;...
Autoimmune thyroid disease	-2.01	0.00e+0	46/53 (86.79%)	IL2;IL4;IFNA7;...
Ribosome	-2.06	0.00e+0	113/158 (71.52%)	RPS3A;RPS11;RPS20;...
Graft-versus-host disease	-2.11	0.00e+0	32/42 (76.19%)	CD86;HLA-F;HLA-DOB;...
Type I diabetes mellitus	-2.19	0.00e+0	38/43 (88.37%)	CD86;HLA-F;HSPD1;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone

Osteosarcoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
U-2 OS	CVCL_0042	Homo sapiens	10uM	6H	Hide ▲

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	0.01uM - 10uM	6H, 24H	Hide ▲
MDA-MB-231	CVCL_0062	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Breast epithelium

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF-10A	CVCL_0598	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Cervix

Cervical adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HeLa	CVCL_0030	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Normal (Transformed)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HEK293	CVCL_0045	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Pancreas

Pancreatic carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
YAPC	CVCL_1791	Homo sapiens	0.01uM - 10uM	24H	Show ▼

Peripheral blood

Acute monocytic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
THP-1	CVCL_0006	Homo sapiens	0.04uM - 10uM	24H	Show ▼

T-cell acute lymphoblastic leukemia

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Jurkat	CVCL_0367	Homo sapiens	0.04uM - 10uM	24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	0.01uM - 10uM	6H, 24H	Show ▼

Umbilical vein

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HUVEC-C	CVCL_2959	Homo sapiens	0.04uM - 10uM	24H	Show ▼